Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials
BB Reeve, SA Mitchell, AC Dueck… - JNCI: Journal of the …, 2014 - academic.oup.com
Background The National Cancer Institute’s Symptom Management and Health-Related
Quality of Life Steering Committee held a clinical trials planning meeting (September 2011) to …
Quality of Life Steering Committee held a clinical trials planning meeting (September 2011) to …
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the …
Patient-reported outcomes (PROs), such as symptoms, function, and other health-related
quality-of-life aspects, are increasingly evaluated in cancer randomised controlled trials (RCTs) …
quality-of-life aspects, are increasingly evaluated in cancer randomised controlled trials (RCTs) …
SPIRIT-PRO Extension explanation and elaboration: guidelines for inclusion of patient-reported outcomes in protocols of clinical trials
…, L Campbell, JC Cappelleri, H Draper, AC Dueck… - BMJ open, 2021 - bmjopen.bmj.com
Patient-reported outcomes (PROs) are used in clinical trials to provide valuable evidence on
the impact of disease and treatment on patients’ symptoms, function and quality of life. High-…
the impact of disease and treatment on patients’ symptoms, function and quality of life. High-…
[HTML][HTML] Global vascular guidelines on the management of chronic limb-threatening ischemia
…, S Cheng, J Dawson, ES Debus, A Dueck… - European Journal of …, 2019 - Elsevier
Guideline Summary Chronic limb-threatening ischemia (CLTI) is associated with mortality,
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused …
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are focused …
Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)
…, SB Clauser, LM Minasian, AC Dueck… - Journal of the …, 2014 - academic.oup.com
The standard approach for documenting symptomatic adverse events (AEs) in cancer clinical
trials involves investigator reporting using the National Cancer Institute’s (NCI’s) Common …
trials involves investigator reporting using the National Cancer Institute’s (NCI’s) Common …
[PDF][PDF] Validity and reliability of the US National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO …
Importance To integrate the patient perspective into adverse event reporting, the National
Cancer Institute developed a patient-reported outcomes version of the Common Terminology …
Cancer Institute developed a patient-reported outcomes version of the Common Terminology …
[HTML][HTML] Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden …
RM Emanuel, AC Dueck, HL Geyer… - Journal of clinical …, 2012 - ncbi.nlm.nih.gov
Purpose Myeloproliferative neoplasm (MPN) symptoms are troublesome to patients, and
alleviation of this burden represents a paramount treatment objective in the development of …
alleviation of this burden represents a paramount treatment objective in the development of …
[HTML][HTML] Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
RJ Caselli, AC Dueck, D Osborne… - … England Journal of …, 2009 - Mass Medical Soc
Background The APOE ε4 allele is associated with the risk of late-onset Alzheimer's disease.
The age at which memory decline diverges among persons who are homozygous for the …
The age at which memory decline diverges among persons who are homozygous for the …
[HTML][HTML] Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant …
…, J Baselga, E De Azambuja, AC Dueck… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
Background Lapatinib (L) plus trastuzumab (T) improves outcomes for metastatic human
epidermal growth factor 2–positive breast cancer and increases the pathologic complete …
epidermal growth factor 2–positive breast cancer and increases the pathologic complete …
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
R Scherber, AC Dueck, P Johansson… - Blood, The Journal …, 2011 - ashpublications.org
Symptomatic burden in myeloproliferative neoplasms is present in most patients and
compromises quality of life. We sought to validate a broadly applicable 18-item instrument (…
compromises quality of life. We sought to validate a broadly applicable 18-item instrument (…